Abstract 832P
Background
MALT1 plays a key role in antigen receptor signalling and preclinical data indicate that MALT1 protease inhibition may have benefit in tumours with dysregulated NF-κB signalling, including activated B-cell-diffuse large B-cell lymphoma (ABC-DLBCL). MALT1 inhibitors are in clinical development as monotherapies and in combination with other agnets for the treatment of oncology and haematology indications, including lymphoma.
Methods
EXS73565 (‘565) was designed using generative design, machine learning and molecular dynamics approaches. The compound was characterised in MALT1 protease assays and DLBCL functional studies. In vivo efficacy of ‘565 was assessed in mouse xenograft models, alone and in combination with the BTK inhibitor ibrutinib. Profiling of ‘565 was undertaken in a range of selectivity and preclinical studies.
Results
‘565 is a potent and selective allosteric inhibitor of the MALT1 protease and inhibits the production of IL-10 and proliferation of DLBCL cells. In ABC-DLBCL xenograft studies, ‘565 demonstrated significant tumour growth inhibition. Tumour target engagement was demonstrated through measurement of the MALT1 protease target, RelB, and effects on NF-κB target genes. In an ABC-DLBCL xenograft model with low sensitivity to single-agent MALT1 and BTK inhibition in vivo, combining ‘565 and ibrutinib provided significant synergistic efficacy. Evaluation of ‘565 showed limited activity against CYP450 enzymes, hepatic and renal transporters. Notably, ‘565 avoids inhibition of UGT1A1 (an enzyme involved in metabolising bilirubin and certain small molecule drugs) in comparison to some clinical stage MALT1 inhibitors which carry a high UGT1A1 inhibition risk.
Conclusions
We describe the characterisation of EXS73565, an allosteric inhibitor of MALT1 which is currently in IND/CTA-enabling studies. Importantly, we show that ‘565 exhibits a low drug-drug interaction and hyperbilirubinemia risk, offering the prospect of fully exploring the potential of MALT1 inhibition as a monotherapy and/or in combination with other targeted agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Exscientia.
Disclosure
M. Gooyit, S. Varzandeh, A. Gavard, S. Robinson, F. Breitgoff, A. Cooke, A. Bradley, M. Dominguez: Financial Interests, Personal, Stocks/Shares: Exscientia; Other, Personal, Full or part-time Employment: Exscientia. A. Payne: Financial Interests, Personal, Stocks/Shares: Exscientia; Non-Financial Interests, Personal, Full or part-time Employment: Exscientia. C. Carvalheda, D. Evans, S. Richards, P. Ray: Other, Personal, Full or part-time Employment: Exscientia. C. Radoux, J. Besnard: Other, Personal, Full or part-time Employment: Exscientia; Financial Interests, Personal, Stocks/Shares: Exscientia.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18